Dr. Rietschel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
777 Old Sawmill River Rd
Tarrytown, NY 10591Phone+1 212-920-6338
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Ruprecht Karl University Faculty of MedicineClass of 1998
Certifications & Licensure
NY State Medical License 2009 - 2026
NJ State Medical License 2009 - 2011
Clinical Trials
- Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Start of enrollment: 2010 Jun 01
Publications & Presentations
PubMed
- 1 citationsThree-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Tr...Biagio Ricciuti, Arielle Elkrief, Jessica Lin, Jianjun Zhang, Joao V Alessi
JTO Clinical and Research Reports. 2024-09-01 - Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.Ana Baramidze, Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Davit Giorgadze
Lung Cancer. 2024-07-01 - 14 citationsFirst-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER...Mustafa Özgüroğlu, Saadettin Kilickap, Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko
The Lancet. Oncology. 2023-09-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
